SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

SRP-1003

SRPT·Sarepta Therapeutics, Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 1/2 (MAD - Multiple Ascending Dose)
Time to market
SRP-1003 is in early-stage clinical development (Phase 1/2 MAD study). If the upcoming data supports advancement, a Phase 3 program would follow, meaning regulatory approval and commercialization are likely several years away (estimated 2029-2031 at the earliest).
Why 5/10
The next hard catalyst is the multiple ascending dose (MAD) data readout for SRP-1003 in DM1, expected by year-end 2026 (Q4 2026). This is an early-stage (Phase 1/2) data readout, not a pivotal/registration readout or PDUFA date. Sarepta has substantial commercial revenue (~$1.25B-$1.3B in 2026 guidance) from its approved DMD franchise, so SRP-1003 is one of several pipeline assets rather than the sole value driver. ImpactScore is 5: a near-term binary catalyst on a meaningful pipeline asset at a company with other programs and commercial revenue.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

The next catalyst is the multiple ascending dose (MAD) data readout for SRP-1003 in DM1, expected by year-end 2026 (Q4 2026, within ~2 months). Positive data could support advancement to Phase 3 and re-rate the stock; negative or equivocal data would likely be viewed as a pipeline setback. The data readout is the single most important near-term pipeline catalyst for Sarepta alongside the SRP-1001 (FSHD) readout.

Price Chart

Loading chart...

Executive Summary

SRP-1003 is Sarepta Therapeutics' investigational RNA-targeted therapy for myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disease with no approved disease-modifying treatments. The drug is in early-stage clinical development, and the next major catalyst is the multiple ascending dose (MAD) data readout expected by year-end 2026 (Q4 2026, within approximately two months). Sarepta is a commercial-stage biotech with ~$1.25B-$1.3B in projected 2026 revenue from its approved Duchenne muscular dystrophy franchise, giving it financial stability to advance pipeline candidates. The stock (SRPT) trades at $17.82 with a ~$1.96B market cap and mixed analyst consensus (mean target $21.64). The MAD data readout is a meaningful near-term catalyst but represents an early-stage pipeline event, not a registration decision.

How It Works

SRP-1003 is an investigational RNA-targeted therapy for myotonic dystrophy type 1 (DM1), a rare genetic neuromuscular disorder. While the exact mechanism is not publicly detailed, Sarepta specializes in antisense oligonucleotides that modulate RNA processing to correct underlying genetic defects. DM1 is caused by a repeated DNA sequence that produces toxic RNA, and SRP-1003 is designed to target that toxic RNA to restore normal cellular function.

Trial Status

SRP-1003 is in an early-stage multiple ascending dose (MAD) study for DM1. The company expects to report MAD data by year-end 2026 (Q4 2026). The data will inform whether the program advances to Phase 3 development.

The Two-Sided Case

▲ Bull Case5
SRP-1003 targets DM1 (myotonic dystrophy type 1), a serious rare neuromuscular disease with no approved disease-modifying therapies, representing a large unmet need and potential blockbuster opportunity.
MAD data readout is imminent (expected Q4 2026, within ~2 months), providing a near-term binary catalyst that could drive significant stock movement.
Sarepta has deep expertise in RNA-targeted therapies and a proven commercial infrastructure from its approved Duchenne muscular dystrophy franchise (PMO portfolio generating ~$240M/quarter).
The company raised full-year 2026 revenue guidance to $1.25B-$1.3B and has nearly $1B in cash, providing ample funding to advance SRP-1003 through development without near-term dilution risk.
BlackRock, State Street, and Goldman Sachs all added to their SRPT positions in Q2 2026, signaling institutional confidence in the pipeline.
▼ Bear Case5
Early-stage MAD data may not support advancement to Phase 3, as flagged in Sarepta's own risk factors from the Q3 2026 earnings filing.
Sarepta has a mixed track record with pipeline candidates beyond its core DMD franchise; DM1 is a biologically challenging indication.
Analyst consensus on SRPT is mixed (only 12 of 31 analysts rate it Buy/Strong Buy, with a mean price target of $21.64 implying modest 21% upside), reflecting skepticism about pipeline value.
Several large institutional holders exited or severely trimmed positions in Q2/Q3 2026, including RA Capital Management (exit), Citadel (exit), and Canada Pension Plan (94% trim).
Short-sale volume has been persistently elevated (frequently 60-74% of off-exchange volume), indicating significant bearish positioning.

Upcoming Catalysts

  • MAD data readout for SRP-1003 (DM1) expected Q4 2026 (by year-end, within ~2 months)
  • MAD data readout for SRP-1001 (FSHD) also expected Q4 2026

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov